Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 10:02 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2545–2568 of 3,602 matching trials from the live ClinicalTrials.gov search.
Conditions
Onychomycosis of Toenail, Onychomycosis
Interventions
plasma treatment
Device
Lead sponsor
DeviceFarm, Inc.
Industry
Eligibility
21 Years to 75 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Sacramento, California
Conditions
Acute Lymphocytic Leukemia, Chronic Myeloid Leukemia, Acute Myelocytic Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders
Interventions
Isolex 300i Stem Cell Selection
Device
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
10 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Weight Loss
Interventions
Weight Loss Phase, HP-IF, HH
Behavioral
Lead sponsor
Skidmore College
Other
Eligibility
30 Years to 65 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Saratoga Springs, New York
Conditions
Recurrent Waldenstrom Macroglobulinemia, Refractory Waldenstrom Macroglobulinemia
Interventions
Pomalidomide
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2025
U.S. locations
1
States / cities
Houston, Texas
Conditions
Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
educational intervention
Other
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
583 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
4
States / cities
Detroit, Michigan • Cleveland, Ohio • Philadelphia, Pennsylvania
Conditions
Bone Marrow Transplantation, Hematopoietic Stem Cells, Multiple Myeloma, Lymphoma
Interventions
Neupogen, Hyperbaric oxygen therapy, Plerixafor
Drug · Procedure
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
21 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Completed Early Phase 1 Interventional Accepts healthy volunteers

Platelet Rich Plasma in Knee Osteoarthritis

NCT05080075
Conditions
Knee Osteoarthritis
Interventions
Platelet Rich Plasma Injection
Biological
Lead sponsor
University of Toledo Health Science Campus
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Toledo, Ohio
Conditions
Multiple Myeloma, Plasma Cell Leukemia
Interventions
Bendamustine
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Multiple Myeloma, Shortness of Breath, Dyspnea, Cardiotoxicity
Interventions
EndoPAT, Blood Pressure Cuff, Echocardiogram, Quality of Life Assessment, Blood Tests
Device · Diagnostic Test · Other
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Nonmalignant Neoplasm
Interventions
trivalent influenza vaccine, Immunoenzyme technique, Laboratory biomarker analysis
Biological · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 120 Years
Enrollment
459 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2013
U.S. locations
2
States / cities
Duarte, California • Pasadena, California
Conditions
Plasma Cell Myeloma
Interventions
Isatuximab SAR650984, Cemiplimab REGN2810
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
4
States / cities
Denver, Colorado • Kansas City, Kansas • New York, New York + 1 more
Conditions
DS Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma, DS Stage III Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions
Busulfan, Melphalan, Bortezomib, Autologous Hematopoietic Stem Cell Transplantation, Peripheral Blood Stem Cell Transplantation
Drug · Procedure
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years to 72 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
4
States / cities
New Brunswick, New Jersey • New York, New York • The Bronx, New York
Conditions
Hematologic Malignancy, Stem Cell Transplant, Bone Marrow Transplant, Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes
Interventions
Intervention website, Enhanced Usual Care (Control) Website
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
356 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Chicago, Illinois • Nutley, New Jersey
Conditions
Multiple Myeloma
Interventions
Velcade, Cyclophosphamide, Revlimid
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Critical Limb Ischemia (CLI), Peripheral Vascular Disease (PVD)
Interventions
Magellan®
Device
Lead sponsor
Arteriocyte, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Acute Myeloid Leukemia, Acute Myeloid Leukemia in Remission, Aplastic Anemia, Chronic Myelomonocytic Leukemia, Hodgkin Lymphoma, Indolent Non-Hodgkin Lymphoma, Malignant Neoplasm, Myelodysplastic Syndrome, Myeloproliferative Neoplasm, Plasma Cell Myeloma, Refractory Anemia, Refractory Anemia With Excess Blasts, Refractory Anemia With Ring Sideroblasts, Refractory Cytopenia With Multilineage Dysplasia, Refractory Cytopenia With Multilineage Dysplasia and Ring Sideroblasts
Interventions
Fludarabine, Total-Body Irradiation, T Cell-Depleted Donor Lymphocyte Infusion, Cyclophosphamide, Peripheral Blood Stem Cell Transplantation, Allogeneic Hematopoietic Stem Cell Transplantation, Tacrolimus, Mycophenolate mofetil, Laboratory Biomarker Analysis
Drug · Radiation · Biological + 2 more
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Central Centrifugal Cicatricial Alopecia
Interventions
Platelet-Rich Plasma (PRP) Injections, Saline
Biological · Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Houston, Texas
Conditions
Waldenstrom's Macroglobulinemia
Interventions
Bortezomib, Rituximab
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Multiple Myeloma, Plasma Cell Myeloma
Interventions
Zirconium Zr 89-DFO-YS5, Positron Emission Tomography / Computed Tomography (PET/CT), Positron Emission Tomography / Magnetic Resonance Imaging (PET/MRI), Fludeoxyglucose F-18
Drug · Procedure · Other
Lead sponsor
Robert Flavell, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
San Francisco, California
Conditions
Relapsed or Refractory Multiple Myeloma
Interventions
Carfilzomib, Dexamethasone, Pomalidomide
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 99 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
13
States / cities
Birmingham, Alabama • Denver, Colorado • New Haven, Connecticut + 8 more
Terminated Phase 1 Interventional Results available

T-cell Receptor α/β Depleted Donor Lymphocyte Infusion

NCT05350163
Conditions
Lymphoid Leukemia, Acute, Myeloid Malignancy, Plasma Cell Tumor
Interventions
T-cell Receptor α/β Depleted Donor Lymphocyte Infusions
Biological
Lead sponsor
Guenther Koehne
Other
Eligibility
18 Years to 74 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Miami, Florida
Conditions
Multiple Myeloma
Interventions
carfilzomib
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
28
States / cities
Mobile, Alabama • Scottsdale, Arizona • Beverly Hills, California + 23 more
Conditions
Acute Myeloid Leukemia, AML, Adult, Multiple Myeloma, Myeloma
Interventions
FT538, Cyclophosphamide, Fludarabine, Daratumumab, Elotuzumab
Drug
Lead sponsor
Fate Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
8
States / cities
Denver, Colorado • Minneapolis, Minnesota • St Louis, Missouri + 5 more
Conditions
Anal Fistula
Interventions
Surgery, Platelet-rich plasma (PRP), Matrix
Procedure · Other · Device
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Houston, Texas